Allergy Diagnostics Market Size To Reach $11.63 Billion By 2030

Allergy Diagnostics Market Growth & Trends

The global allergy diagnostics market size is expected to reach USD 11.63 billion by 2030, registering a CAGR of 10.39% from 2025 to 2030, according to a new report by Grand View Research, Inc. Allergies continue to be a significant public health concern in the U.S. and worldwide, affecting both children and adults across all demographics. According to the CDC’s 2023 National Health Interview Survey (NHIS), approximately 25.7% of adults and 18.9% of children in the U.S. reported being diagnosed with seasonal allergies, eczema, or food allergies. This data highlights the growing prevalence of allergic conditions, reflecting an urgent need for better diagnostic tools and early detection strategies to reduce complications and improve quality of life.

Additionally, statistics from the Allergy & Asthma Network reveal that over 50 million Americans suffer from allergies each year, making them the sixth leading cause of chronic illness in the U.S. Food allergies alone affect an estimated 5.6 million children (around one in 13), and about 26 million adults further underlining the need for precise and accessible diagnostic solutions. Moreover, asthma, which is often triggered by allergens, affects more than 25 million Americans, including 4.2 million children. These figures point to the growing healthcare burden of allergic diseases and support the case for investments in advanced diagnostics and early intervention.

U.S. Demographic Variations:

• Adults:

• Non-Hispanic White adults were more likely to have seasonal allergies (28.4%) compared to Non-Hispanic Black (24%), Hispanic (18.8%), and Non-Hispanic Asian (17%) adults.

• Eczema prevalence was higher among women (8.9%) than men (5.7%).

• Non-Hispanic Black adults had a higher prevalence of food allergies (8.5%) compared to Hispanic (4.4%), Non-Hispanic White (6.2%), and Non-Hispanic Asian (4.5%) adults.

• Children:

• Boys (20%) were more likely to have seasonal allergies than girls (17.7%).

• Children aged 6–11 years had the highest prevalence of eczema (12.1%), followed by those aged 0–5 years (10.4%), and 12–17 years (9.8%).

• Non-Hispanic Black children were more likely to have food allergies (7.6%) compared to Hispanic (5%) and Non-Hispanic White (5.3%) children

The economic impact of allergic diseases is also substantial, costing the U.S. healthcare system billions annually due to emergency visits, hospitalizations, and lost productivity. The combination of rising prevalence, healthcare costs, and the risk of severe allergic reactions has created a compelling market demand for innovative allergy diagnostics that can offer accuracy, speed, and accessibility across various settings, from primary care to specialty clinics and even at-home testing kits.

Some of the key players in the global allergy diagnostics market include Thermo Fisher Scientific, Inc., HYCOR Biomedical, EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.), Omega Diagnostics Group PLC, Lincoln Diagnostics, Inc., AESKU.GROUP GmbH, Minaris Medical America, Inc., HOB Biotech Group Corp., Ltd., DASIT Group SPA, R-Biopharm AG, bioMérieux, and Siemens Healthcare GmbH.

These companies are actively engaged in strategic initiatives such as new product launches, regulatory approvals, and technology advancements to strengthen their global market presence and expand their allergy testing portfolios. For instance, in May 2022, Thermo Fisher Scientific expanded its allergy diagnostics offering in the U.S. by launching its Phadia 2500+ series for high-throughput in vitro allergy and autoimmune testing, enhancing lab efficiency and precision diagnostics. This launch supports the growing demand for comprehensive allergy panels and molecular-level testing, addressing increasing cases of food and respiratory allergies, particularly in aging and pediatric populations across key markets like the U.S. and Europe.

 Request a free sample copy or view report summary: Allergy Diagnostics Market Report

Allergy Diagnostics Market Report Highlights

• Based on products and services, consumables accounted for the largest revenue share of 63.14% in 2024. This dominance is attributed to the frequent need for replenishment of reagents, test kits, and other consumable materials essential for allergy testing procedures, as well as the increasing volume of allergy diagnostic tests conducted globally.

• Based on allergen, inhaled dominated the market and accounted for the largest revenue share of 49.72% in 2024. This is primarily due to the high prevalence of respiratory allergies caused by airborne allergens such as pollen, dust mites, mold spores, and animal dander, which necessitate widespread and routine diagnostic testing.

• Based on test type, the in vitro test led the market with the highest revenue share in 2024. The preference for in vitro tests is driven by their safety, reproducibility, and ability to provide comprehensive panels that can detect multiple allergens simultaneously, making them a preferred choice in both clinical and research settings.

• Based on end use, hospitals and clinics held the highest revenue share of 37.23% in 2024. This is due to the growing integration of allergy diagnostics into hospital outpatient services, increasing referrals for specialized allergy care, and the demand for accurate, laboratory-based testing within clinical settings.

• Based on region, North America led the global market, accounting for 36.53% of the revenue in 2024. This dominance is attributed to the region's well-established healthcare infrastructure, high awareness of allergy-related health risks, strong reimbursement policies, and the presence of key industry players offering advanced diagnostic solutions.

• The Asia Pacific region is projected to witness the fastest growth, with a CAGR of 11.43% from 2024 to 2030. Factors driving this growth include rising urbanization, increasing environmental pollution, changing dietary habits leading to new food allergies, and expanding access to healthcare services, particularly in emerging economies such as China and India.

Allergy Diagnostics Market Segmentation

Grand View Research has segmented the global allergy diagnostics market based on products and services, allergen, test type, end use, and region:

Allergy Diagnostics Products and Services Outlook (Revenue, USD Million, 2018 - 2030)

• Instruments

• Consumables

• Services

Allergy Diagnostics Allergen Outlook (Revenue, USD Million, 2018 - 2030)

• Food

  • Dairy Products

  • Poultry Product

  • Tree Nuts

  • Peanuts

  • Shellfish

  • Wheat

  • Soys

  • Other Food Allergens

• Inhaled

• Drug

• Other Allergens

Allergy Diagnostics Test Type Outlook (Revenue, USD Million, 2018 - 2030)

• In Vivo Test

  • Skin Prick Test

  • Intradermal Test

  • Patch Test

• In vitro Test

Allergy Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals & Clinics

• Diagnostics Laboratories

• Research Institutions

• Others

Allergy Diagnostics Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in the Allergy Diagnostics Market

• Thermo Fisher Scientific, Inc.

• HYCOR Biomedical

• EUROIMMUN Medizinische Labordiagnostika AG (PerkinElmer, Inc.)

• Omega Diagnostics Group PLC

• Lincoln Diagnostics, Inc.

• AESKU.GROUP GmbH

• Minaris Medical America, Inc.

• HOB Biotech Group Corp., Ltd.

• DASIT Group SPA

• R-Biopharm AG

• bioMérieux

• Siemens Healthcare GmbH